Virus News and Research

Latest Virus News and Research

Infectious diseases specialist from Walter and Eliza Hall Institute receives Frank Fenner Award

Infectious diseases specialist Dr Marc Pellegrini from the Walter and Eliza Hall Institute will today receive the Frank Fenner Award from the Australasian Society for Infectious Diseases, recognising Dr Pellegrini's efforts to understand human responses to chronic infections.

28 May 2010

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Roche Diagnostics announced today that the U.S. Food and Drug Administration (FDA) granted Premarket Approval for its Elecsys Antibody to hepatitis C virus (anti-HCV) assay. The Elecsys Anti-HCV assay is an in-vitro diagnostic test for the qualitative detection of total antibodies to hepatitis C virus in human serum or plasma.

From Roche Sequencing and Life Science 28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

Researchers study safety and immunogenicity of two H1N1 vaccines in UK children

The first head to head study of the two H1N1 vaccines used in the UK during the recent pandemic finds that the adjuvanted split virus vaccine induced higher immune response rates in young children, but was associated with more reactions than the whole virus vaccine.

28 May 2010

ART associated with reduced risk of HIV transmission to sexual partners, study shows

Research published in the Lancet online Thursday "provides the strongest evidence to date" that antiretroviral therapy might also be used to prevent transmission of HIV, Agence France-Presse reports. The observational study found that treating HIV-positive patients with ART reduced the risk of HIV transmission to their sexual partners by 92 percent (5/26).

28 May 2010

ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today The AIDS Research Consortium of Atlanta has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc.

28 May 2010

Computer virus infects scientist

A scientist at the University of Reading has become the first person in the world to be infected by a computer virus.

27 May 2010

Fear of H1N1 appears to be the driving factor behind adoption of preventive behaviors: Study

Fear of the H1N1 virus appears to be the driving factor behind the adoption of preventive behaviors, according to a study published in the June issue of AJIC: American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

27 May 2010

Modified measles virus may hold potential for treatment of medulloblastoma

The use of modified measles virus may represent a new treatment for a childhood brain tumor known as medulloblastoma, according to a new study appearing in Neuro-Oncology.

27 May 2010

KPBS examines microbicide research as M2010 concludes

KPBS reports on researchers' efforts to develop novel methods to protect women from HIV infection that have been examined at the International Microbicides Conference (M2010) in Pittsburgh this week. In sub-Saharan Africa, one of the region's hardest hit by HIV/AIDS, "six out of ten adults living with the virus are women," KPBS writes.

27 May 2010

Experimental Hendra virus treatment offered to mother and daughter

After recent reports of a horse being put down for being infected with the deadly Hendra virus, new reports of an experimental treatment have surfaced. At Queensland's Sunshine Coast a mother and daughter duo, Rebecca Day and her 12 year old girl Mollie, who had been exposed to the virus, have been offered the experimental treatment.

27 May 2010

FDA approves Mylan's ANDA for Valacyclovir Hydrochloride Tablets

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Valacyclovir Hydrochloride Tablets, 500 mg (base) and 1000 mg (base), the generic version of GlaxoSmithKline's Valtrex, a treatment for the herpes virus infection.

26 May 2010

A step closer to a universal influenza virus vaccine

Researchers at Mount Sinai School of Medicine have developed a new influenza vaccine that brings science one step closer to a universal influenza vaccine that would eliminate the need for seasonal flu shots. The new findings can be found in the inaugural issue of mBio-, the first online, open-access journal published by the American Society for Microbiology.

26 May 2010

Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development

Presidio Pharmaceuticals, Inc. announced today that they have selected a second clinical candidate, PPI-1301, from their hepatitis C virus (HCV) NS5A program for advancement into clinical development. Presidio's first NS5A inhibitor, PPI-461, is currently undergoing evaluation in a Phase 1a clinical study.

26 May 2010

Antiviral treatment, SVR prevent esophageal varices in patients with HCV-induced cirrhosis

Italian researchers have discovered that antiviral treatment and sustained virologic response prevents esophageal varices in patients with compensated hepatitis C -induced cirrhosis, indicating that endoscopic surveillance can be safely delayed or avoided in these patients. Full findings are published in the June issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

26 May 2010

RSV appears to be predominant among Kenyan children hospitalized with severe pneumonia: Study

Among infants and children hospitalized in Kenya with severe pneumonia, respiratory syncytial virus appears to be the predominant virus detected, according to a study in the May 26 issue of JAMA.

26 May 2010

Researchers present more findings for microbicides, prep at M2010 conference

Researchers on Monday at the International Microbicides Conference in Pittsburgh continued to present data on HIV prevention research, Reuters reports. The news service outlines several prevention methods being researched, including an intravaginal ring that over time releases two antiretrovirals - dapivirine and maraviroc - for up to a month, and a vaginal tablet that time-releases the antiretrovirals dapivirine and DS003 for up to 12 hours.

26 May 2010

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

A study conducted by researchers at the Cleveland Clinic finds that patients suffering from cirrhosis preceded by nonalcoholic steatohepatitis are at an equal risk of developing hepatocellular carcinoma than those who develop cirrhosis resulting from hepatitis C virus. Results of this study appear in the June issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

26 May 2010

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vertex Pharmaceuticals Incorporated today announced that 75% of people chronically infected with genotype 1 hepatitis C virus (HCV) who had not previously been treated achieved a sustained viral response (SVR or viral cure) after receiving a 12-week telaprevir-based combination regimen, followed by treatment with pegylated-interferon and ribavirin alone, in the Phase 3 ADVANCE trial.

26 May 2010

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

Vical Incorporated announced today that the company is collaborating with leading pediatric infectious disease researchers Stuart P. Adler, M.D., and Michael A. McVoy, Ph.D., of Virginia Commonwealth University under a five-year, approximately $4.0 million grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

25 May 2010

Virus News and Research

Latest Virus News and Research

Infectious diseases specialist from Walter and Eliza Hall Institute receives Frank Fenner Award

FDA grants Premarket Approval for Roche Diagnostics' Elecsys Antibody to hepatitis C virus assay

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Researchers study safety and immunogenicity of two H1N1 vaccines in UK children

ART associated with reduced risk of HIV transmission to sexual partners, study shows

ARCA receives approval to begin enrollment of first therapeutic trial with GeoVax vaccine

Computer virus infects scientist

Fear of H1N1 appears to be the driving factor behind adoption of preventive behaviors: Study

Modified measles virus may hold potential for treatment of medulloblastoma

KPBS examines microbicide research as M2010 concludes

Experimental Hendra virus treatment offered to mother and daughter

FDA approves Mylan's ANDA for Valacyclovir Hydrochloride Tablets

A step closer to a universal influenza virus vaccine

Presidio Pharmaceuticals to advance PPI-1301 inhibitor from HCV NS5A program into clinical development

Antiviral treatment, SVR prevent esophageal varices in patients with HCV-induced cirrhosis

RSV appears to be predominant among Kenyan children hospitalized with severe pneumonia: Study

Researchers present more findings for microbicides, prep at M2010 conference

NASH-induced cirrhosis is greater risk factor for HCC: Cleveland Clinic study

Vertex reports 75% patients with HCV achieve viral cure with 12-week telaprevir-based combination regimen

Vical receives $4.0M grant to support development of novel vaccine for CMV infection

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in